PUBLISH ONLY Journal of Thoracic Oncology

Slides:

Advertisements

Similar presentations

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Advertisements

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

PUBLISH ONLY Journal of Thoracic Oncology

Ratio of Metastatic Lymph Nodes to Total Number of Nodes Resected is Prognostic for Survival in Esophageal Carcinoma Clive J. Kelty, MB, ChB, PhD, FRCSEd,

E13-01: Insights into thymic epithelial tumor: pathology

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection Morihito Okada,

Brett W. Carter, MD, Edith M. Marom, MD, Frank C. Detterbeck, MD

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

NA Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Frank Detterbeck, MD Journal of Thoracic Oncology

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer Yingwei.

LKB1 Regulated Pathways in Lung Cancer Invasion and Metastasis

Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non–Small Cell Lung Cancer in the U.S. National Cancer Data Base

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Richard J Gralla, MD, Frank Griesinger, MD, PhD

PS02.17 A Biomarker-Driven Algorithm for Sequencing of Systemic Therapy for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Survey of 25 Investigators

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Heidi B. Rolke, Frode Gallefoss Journal of Thoracic Oncology

Mitotic Inhibitors Journal of Thoracic Oncology

The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer Thomas E. Stinchcombe, MD, Harry.

P3-255: Tumor size as a prognostic factor for the survival of surgically treated stage Ia non-small cell carcinoma Gustavo A. Lyons, Silvia Quadrelli,

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,

Surgical Treatment of Recurrent Thymomas

Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

ES Lung Cancer Surgery for High Risk Patients

Visceral Pleural Invasion Classification in Non-small Cell Lung Cancer

MTP13-01: Indications and limitations of bronchoscopy

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Lymphovascular Invasion in Non–Small-Cell Lung Cancer: Implications for Staging and Adjuvant Therapy Kristin A Higgins, MD, Junzo P Chino, MD, Neal Ready,

Clinical Relevance of Our Multimodality Prognostic Score

It’s All in the “Swerve of the Curve”

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Systematic Evaluation of Genetic Variants in Three Biological Pathways on Patient Survival in Low-Stage Non-small Cell Lung Cancer V. Shane Pankratz,

MTP19-01: T4 N0/N1 nonsmall cell lung cancer can be cured as a first line treatment with an expected five year survival rate as high as 43% provided a.

International Thymic Malignancies Interest Group: A Way Forward

European Lung Cancer Conference (ELCC) 2016 Organisation

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

IASLC 6th Latin American Conference on Lung Cancer

OA Survival Trends Among Non-Small Cell Lung Cancer (NSCLC) Patients Over A Decade: Impact of Initial Therapy at Academic Centers B. Dholaria,

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Review of First-Line Treatment for Small-cell Lung Cancer

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Mark A. Socinski, MD Journal of Thoracic Oncology

Elevated Preoperative C-reactive Protein Predicts Poor Cancer Specific Survival in Patients Undergoing Resection for Non-small Cell Lung Cancer Caroline.

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

PUBLISH ONLY Journal of Thoracic Oncology Journal of Thoracic Oncology Volume 10, Issue 9, Pages S761-S790 (September 2015) DOI: 10.1016/S1556-0864(16)30013-2 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

fig. 1 A: arrival; B: away; C: near; D: far. Conclusion: Adjuvant therapy and depth of invasion are independent factors influencing prognosis of en-bloc resected chest wall involving non-small cell lung cancers, the role of tumor's location needs more investigations. Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10.1016/S1556-0864(16)30013-2) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10 Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10.1016/S1556-0864(16)30013-2) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10 Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10.1016/S1556-0864(16)30013-2) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 overall survival for initial diagnosis among patients with bone metastasis, extraosseous metastasis at diagnosis, both bone and extraosseous metastasis at diagnosis, and only bone metastasis at diagnosis. Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10.1016/S1556-0864(16)30013-2) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10 Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10.1016/S1556-0864(16)30013-2) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10 Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10.1016/S1556-0864(16)30013-2) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10 Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10.1016/S1556-0864(16)30013-2) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10 Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10.1016/S1556-0864(16)30013-2) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10 Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10.1016/S1556-0864(16)30013-2) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10 Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10.1016/S1556-0864(16)30013-2) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10 Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10.1016/S1556-0864(16)30013-2) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10 Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10.1016/S1556-0864(16)30013-2) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10 Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10.1016/S1556-0864(16)30013-2) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 The relationship between the modified Glasgow prognostic score [score: 0, 1, 2 from top to bottom) and overall survival in patients with limited-stage small cell lung cancer (p = 0.046). Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10.1016/S1556-0864(16)30013-2) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 The relationship between the CPR combined with LDH (score: 0, 1, 2, from top to bottom) and overall survival in patients with limited-stage small cell lung cancer [p=0.003). Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10.1016/S1556-0864(16)30013-2) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10 Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10.1016/S1556-0864(16)30013-2) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10 Journal of Thoracic Oncology 2015 10, S761-S790DOI: (10.1016/S1556-0864(16)30013-2) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions